Do younger adult patients with hypertensive intracerebral hemorrhage have higher prevalence of comorbidities such as diabetes and worse clinical outcomes in comparison to older patients with this condition? Read on to find out more.
Psychiatric patients are susceptible to cardiovascular disease (CVD), but this risk is poorly understood. This study compared CVD risk in psychiatric patients taking weight gain-inducing drugs with that in the general population.
How soon is too soon to look for metabolic syndrome in your patients with schizophrenia? This randomized open-label trial investigates 7 risk factors of 5 atypical and 2 typical antipsychotics to make recommendations for monitoring metabolic measurements.
Vitamin B12 deficiency is associated with various psychiatric symptoms. This study assessed the pattern of serum folate and vitamin B12 levels in psychiatric inpatients compared to nonpsychiatric controls in India.
Abnormal thyroid hormone levels are among the most common nonpsychiatric causes of mood and anxiety symptoms. This retrospective study examines the extent of the issue in youth with mood and anxiety disorders and suggests a need for targeted screening.
How does a patient's resilience level and history of childhood adversity impact his or her health? This study evaluated 114 schizophrenia patients and 101 comparison subjects to determine the relationships among mental and physical illness, childhood trauma, and resilience.
Recent studies aimed at the development of personalized pharmacotherapy have identified CYP enzymes and transporters as important determinants of variability in drug disposition and response. Along these lines, this study used phenotyping in 64 patients to investigate the association between CYP and P-glycoprotein activities and plasma antidepressant concentration.
Identification of physiologic biomarker precursors that result from prolonged psychological stress allows for possible prevention of negative outcomes; however, long-term data on the association of trauma with such biomarkers are lacking. Read this article to learn if captivity-related stress was related to metabolic syndrome and blood levels of C-reactive protein over time in a group of combat veterans.
The struggle to identify patients most at risk for metabolic complications of antipsychotic use is ongoing. The authors of this study identified potential correlations between baseline plasma insulin level and shifts in metabolic status in psychiatric inpatients. Read their article to find out more.
The shorter life expectancy in patients with psychotic disorders is largely due to an increased risk of obesity, diabetes, and cardiovascular disease. This comparison of youths with first-episode psychosis and healthy controls may better our understanding of treatment-independent risk factors present before antipsychotic exposure.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”